{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:10:03Z","timestamp":1759047003421,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.imlet.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T10:39:48Z","timestamp":1570271988000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model"],"prefix":"10.1016","volume":"216","author":[{"given":"So-Hee","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Seop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunwoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2019.10.005_bib0005","first-page":"373","article-title":"Diabetes: Islet transplantation for T1DM","volume":"12","author":"Ridler","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.imlet.2019.10.005_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.mpa.0000203961.16630.2f","article-title":"Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes","volume":"32","author":"Balamurugan","year":"2006","journal-title":"Pancreas"},{"key":"10.1016\/j.imlet.2019.10.005_bib0015","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.imlet.2019.10.005_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1188\/04.CJON.473-480","article-title":"Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications","volume":"8","author":"Colson","year":"2004","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.imlet.2019.10.005_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.imlet.2019.10.005_bib0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2005-05-1820","article-title":"NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145","volume":"107","author":"Vodanovic-Jankovic","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djj309","article-title":"Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis","volume":"98","author":"Brignole","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.imlet.2019.10.005_bib0040","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.10.005_bib0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.10.005_bib0050","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2019.10.005_bib0055","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/TP.0b013e3181bd7b3a","article-title":"Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates","volume":"88","author":"Kim","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.imlet.2019.10.005_bib0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2019.10.005_bib0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705628","article-title":"Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells","volume":"39","author":"Coenen","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.imlet.2019.10.005_bib0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.trim.2007.10.007","article-title":"Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion","volume":"18","author":"Horibe","year":"2008","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.imlet.2019.10.005_bib0080","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db06-0173","article-title":"Sirolimus is associated with reduced islet engraftment and impaired beta-cell function","volume":"55","author":"Zhang","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.imlet.2019.10.005_bib0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1432-2277.2008.00743.x","article-title":"Rapamycin in islet transplantation: friend or foe?","volume":"22","author":"Berney","year":"2009","journal-title":"Transpl. Int."},{"key":"10.1016\/j.imlet.2019.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/TP.0b013e31818aa43c","article-title":"Pancreatic islets induce CD4(+) [corrected] CD25(-)Foxp3(+) [corrected] T-cell regulated tolerance to HY-mismatched skin grafts","volume":"86","author":"Yoon","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.imlet.2019.10.005_bib0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4049\/jimmunol.165.1.247","article-title":"An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts","volume":"165","author":"Diamond","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2019.10.005_bib0100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00007890-199904150-00006","article-title":"Immune mechanisms associated with the rejection of fetal murine proislet allografts and pig proislet xenografts: comparison of intragraft cytokine mRNA profiles","volume":"67","author":"Simeonovic","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.imlet.2019.10.005_bib0105","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/01.tp.0000250731.44913.ee","article-title":"Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells","volume":"82","author":"Xia","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.imlet.2019.10.005_bib0110","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.178.4.2221","article-title":"Abrogation of antibody-mediated allograft rejection by regulatory CD4 T cells with indirect allospecificity","volume":"178","author":"Callaghan","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2019.10.005_bib0115","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.imlet.2019.10.005_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.imlet.2019.10.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/xen.12533","article-title":"Peri\u2010graft porcine\u2010specific CD4+ FoxP3+ regulatory T cells by CD40\u2010CD154 blockade prevented the rejection of porcine islet graft in diabetic mice","author":"Yoon","year":"2019","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.imlet.2019.10.005_bib0130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20020190","article-title":"Interleukin 2 signaling is required for CD4(+) regulatory T cell function","volume":"196","author":"Furtado","year":"2002","journal-title":"J. Exp. Med."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781930361X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781930361X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:35:35Z","timestamp":1759044935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524781930361X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":26,"alternative-id":["S016524781930361X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2019.10.005","relation":{},"ISSN":["0165-2478"],"issn-type":[{"type":"print","value":"0165-2478"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}